Pancreatic and Hepatic Oncology ResearchGastric Cancer Management and OutcomesCancer Research and TreatmentsCancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer
Publications
184
Citations
2,337
Est. group size
~3
Recurring co-author estimate
Active years
25
Publishing since 2002
Publication cadence
Publications per year over the last 10 years — averaging 15.6/year recently
Recent publications
- Abstract 3053: SHP2 inhibition with RMC4630 demonstrates antitumor efficacy and potentiates nanoparticle-paclitaxel response in pancreatic cancer
Cancer Research · 2025
- Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models
Journal of Cellular and Molecular Medicine · 2024
- Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
Frontiers in Oncology · 2023
- Supplementary Figure from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Supplementary Figure from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Data from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Data from A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
2023
- Data from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Data from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Supplementary Figure 1 from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Supplementary Figure 1 from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Supplementary Figure Legend from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Supplementary Figure Legend from BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
2023
- Supplementary Figure 1 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
2023
- Supplementary Figure 5 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
2023
Publishes in
- Cancer Research×28
- Journal of Clinical Oncology×4
- PMC×4
- Journal of Cellular and Molecular Medicine×3
- Molecular Cancer Therapeutics×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile